GSK to Invest $30 Billion in R&D and Manufacturing in the United States
Introduction:
GSK plc has announced plans to invest $30 billion across the United States over the next five years in research and development and supply chain infrastructure. The investment aims to strengthen GSK’s innovation and manufacturing capabilities in the U.S., producing products domestically for the American market.
Features:
The investment involves $1.2 billion for advanced manufacturing facilities and AI-driven technologies.
This covers the construction of a new biologics flex factory at Upper Merion, Pennsylvania, which will develop medicines for respiratory diseases such as COPD and asthma, as well as for various cancers.
Expansion of drug substance manufacturing capabilities.
New and improved device and auto-injector production and assembly.
Over the next five years, with key facilities like the Upper Merion flex factory starting construction in 2026.
Specifications:
| Name | GSK |
| Budget | $30 Billion |
| Type | Construction |
| Year of Completion | 2030 |
